Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer
J. Nishijima(Yamaguchi University), Hideyasu Matsuyama(Yamaguchi University), Kazuhiro Nagao, V. GKOLEIZAKIS(Klinik Niederrhein), Kazunori Sasaki, Koji Kobayashi(Yamaguchi University), Jan Fichtner(Klinik Niederrhein), Kenzou Ikemoto(Yamaguchi University), Takahito Hara(Takeda (Japan)), Hikaru Matsumoto(Yamaguchi University), Atunori Oga(Yamaguchi University), Yuko Kawai(Yamaguchi University)
Cited by 10
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116
Androgen Receptor and Invasion in Prostate Cancer
|Cancer Research|2008|115